Focusing on key innovations

The year 2011 was a pivotal year for research and development at Sanofi. Dr. Elias Zerhouni implemented a new worldwide organizational structure for this strategic motor of the Group, with the ambition of creating four innovation hubs located in the United States, France, Germany and Asia. Teams within the R&D structure are open and interconnected, thus creating a foundation for a unique and accessible body of knowledge in the fields of medicines, vaccines, biotechnologies and animal health.
Five priority fields of disease have been defined: diabetes, oncology, inflammatory diseases, ageing, and rare diseases.

A critical look at the R&D portfolio. Three projects are currently in Phase III testing : a new formulation of insulin glargine to treat type-2 diabetes; SAR302503, a JAK-2 inhibitor, for the treatment of myelofibrosis; Fluzone® and VaxiGrip®, quadrivalent inactivated influenza vaccines.

Read more